Scholars Central

Conference abstractPublished 8 Jun 2022

Targeting the reprogrammed energy generation system of metastatic cancer cells-A therapeutic approach

Authors: Uri Nir

Bar-Ilan University, Israel

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The aspiration to achieve efficacious cancer targeted therapy involves intense global R&D efforts. Blockage of fundamental processes like the unique reprogramed energy generation system of malignant cells, combined with a nano-technology approach, should offer new tools for efficient interference with cancer progression. While deciphering the energy generation systems of cancer cells we found that two related enzymes (kinases), termed Fer and FerT, which normally reside in the energy power-station-mitochondria of sperm cells, are harnessed to the reprogrammed mitochondria of cancer cells. Both enzymes potentiate the generation of energy by mitochondria in cancer cells subjected to stress conditions like nutrient and oxygen deprivation. This enables the survival of cancer cells under harsh conditions which are prevalent in solid tumors and during metastatic dessimination. To translate these findings into a novel anti-cancer therapy we have combined, synthetic-chemistry, robotic, and high throughput screening approaches, for the development of a synthetic low molecular weight compound which binds and inhibit the kinase activity of both Fer and FerT. Such a compound termed E260 was then formulated and incorporated into nano-micelles to selectively target Fer and FerT in the mitochondria of malignant cells. Notably, the formulated E260 compound selectively and very efficiently perturbs mitochondrial functioning in non-metastatic and metastatic malignant cells, thereby imposing evoking energy crisis and consequent necrotic death in cancer, but not in normal cells. The anti- cancer therapeutic potency of the E260 formulation is also manifested in-vivo, against metastatic human tumors derived-xenografts, elicited in mice, thus portraying it as a new potential anti-cancer drug. Accordingly, E260 is now being progressed toward FDA approval for human clinical trials.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Uri Nir”